Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John R Corboy

Showing results (41-50 of 89) with videos related to

Pageof 9
Sort By:
Archives of Neurology|April 13, 2005
Initial evaluations for multiple sclerosis in a university multiple sclerosis center: outcomes and role of magnetic resonance imaging in referralMario J Carmosino, Kristin M Brousseau, David B Arciniegas, et al.
Neurology. Clinical Practice|May 2, 2019
Message from the Editors to our ReviewersJohn R Corboy, Laura B Powers, David C Anderson, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|February 27, 2015
Patient perspectives on physician conflict of interest in industry-sponsored clinical trials for multiple sclerosis therapeuticsAndrew J Solomon, Eran P Klein, John R Corboy, et al.
Neurology|February 2, 2018
Efficacy of Balance and Eye-Movement Exercises for Persons With Multiple Sclerosis (BEEMS)Jeffrey R Hebert, John R Corboy, Timothy Vollmer, et al.
Annals of Clinical and Translational Neurology|April 24, 2024
Shifting patterns of multiple sclerosis treatment in a highly prevalent United States populationSue Kwon, Stefan Sillau, John R Corboy, et al.
Frontiers in Neurology|February 11, 2022
Evolution of Disease Modifying Therapy Benefits and Risks: An Argument for De-escalation as a Treatment Paradigm for Patients With Multiple SclerosisBrandi L Vollmer, Andrew B Wolf, Stefan Sillau, et al.
Annals of Clinical and Translational Neurology|August 9, 2020
Rituximab versus natalizumab, fingolimod, and dimethyl fumarate in multiple sclerosis treatmentBrandi L Vollmer, Kavita Nair, Stefan Sillau, et al.
Annals of Clinical and Translational Neurology|August 9, 2020
Serious safety events in rituximab-treated multiple sclerosis and related disordersBrandi L Vollmer, Asya I Wallach, John R Corboy, et al.
Annals of Clinical and Translational Neurology|March 9, 2019
Natalizumab versus fingolimod and dimethyl fumarate in multiple sclerosis treatmentBrandi L Vollmer, Kavita V Nair, Stefan Sillau, et al.
Journal of Clinical and Experimental Neuropsychology|March 17, 2007
MS vs. HD: can white matter and subcortical gray matter pathology be distinguished neuropsychologically?Jose M Lafosse, John R Corboy, Maureen A Leehey, et al.
Pageof 9

Showing results (41-50 of 89) with videos related to

Sort By:
Pageof 9
Archives of Neurology|April 13, 2005
Initial evaluations for multiple sclerosis in a university multiple sclerosis center: outcomes and role of magnetic resonance imaging in referralMario J Carmosino, Kristin M Brousseau, David B Arciniegas, et al.
Neurology. Clinical Practice|May 2, 2019
Message from the Editors to our ReviewersJohn R Corboy, Laura B Powers, David C Anderson, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|February 27, 2015
Patient perspectives on physician conflict of interest in industry-sponsored clinical trials for multiple sclerosis therapeuticsAndrew J Solomon, Eran P Klein, John R Corboy, et al.
Neurology|February 2, 2018
Efficacy of Balance and Eye-Movement Exercises for Persons With Multiple Sclerosis (BEEMS)Jeffrey R Hebert, John R Corboy, Timothy Vollmer, et al.
Annals of Clinical and Translational Neurology|April 24, 2024
Shifting patterns of multiple sclerosis treatment in a highly prevalent United States populationSue Kwon, Stefan Sillau, John R Corboy, et al.
Frontiers in Neurology|February 11, 2022
Evolution of Disease Modifying Therapy Benefits and Risks: An Argument for De-escalation as a Treatment Paradigm for Patients With Multiple SclerosisBrandi L Vollmer, Andrew B Wolf, Stefan Sillau, et al.
Annals of Clinical and Translational Neurology|August 9, 2020
Rituximab versus natalizumab, fingolimod, and dimethyl fumarate in multiple sclerosis treatmentBrandi L Vollmer, Kavita Nair, Stefan Sillau, et al.
Annals of Clinical and Translational Neurology|August 9, 2020
Serious safety events in rituximab-treated multiple sclerosis and related disordersBrandi L Vollmer, Asya I Wallach, John R Corboy, et al.
Annals of Clinical and Translational Neurology|March 9, 2019
Natalizumab versus fingolimod and dimethyl fumarate in multiple sclerosis treatmentBrandi L Vollmer, Kavita V Nair, Stefan Sillau, et al.
Journal of Clinical and Experimental Neuropsychology|March 17, 2007
MS vs. HD: can white matter and subcortical gray matter pathology be distinguished neuropsychologically?Jose M Lafosse, John R Corboy, Maureen A Leehey, et al.
Pageof 9